CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens
Jerin Thomas1, Addison Klebanov2, Sahara John2, Larry S. Miller3, Anil Vegesna2, Richard L. Amdur4, Krishanu Bhowmick2 and Lopa Mishra2,5
1 Donald and Barbara Zucker School of Medicine, Hempstead, NY 11549, USA
2 The Institute for Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhassett, NY 11030, USA
3 Department of Medicine, The Institute for Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Division of Gastroenterology, Northwell Health, Manhassett, NY 11030, USA
4 Quantitative Intelligence Unit, The Institutes for Health Systems Science and Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhassett, NY 11030, USA
5 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
Correspondence:
Lopa Mishra, email:[email protected]
Larry S. Miller, email:[email protected]
Krishanu Bhowmick, email:[email protected]
Keywords: CEACAMs; cancer; immunology; inflammatory diseases
Received: August 24, 2022 Accepted: January 20, 2023 Published: February 01, 2023
Abstract
The CEA family comprises 18 genes and 11 pseudogenes located at chromosome 19q13.2 and is divided into two main groups: cell surface anchored CEA-related cell adhesion molecules (CEACAMs) and the secreted pregnancy-specific glycoproteins (PSGs). CEACAMs are highly glycosylated cell surface anchored, intracellular, and intercellular signaling molecules with diverse functions, from cell differentiation and transformation to modulating immune responses associated with infection, inflammation, and cancer. In this review, we explore current knowledge surrounding CEACAM1, CEACAM5, and CEACAM6, highlight their pathological significance in the areas of cancer biology, immunology, and inflammatory disease, and describe the utility of murine models in exploring questions related to these proteins.
